Recce Pharmaceuticals raises $1.8M

Company News

by Katrina Bullock

Recce Pharmaceuticals (ASX:RCE) has raised $1.8 million via a placement from sophisticated and institutional investors.

The funds were raised to fortify the balance sheet and provide support for its new class of broad spectrum antibiotic.

The antibiotic is in its preclinical pipeline and Recce are working towards approval to start human clinical trials.

12,857,143 fully paid ordinary shares are being issued at $0.14 per share and the company anticipates the placement shares and fee options will be issued on or around 15 February 2019.

Shares in Recce Pharmaceuticals (ASX:RCE) are trading 11.76 per cent lower to $0.15.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.